Skip to content

Xoma to present at endocrinology meet

March 23, 2017

XOMA Corporation (Nasdaq: XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that clinical data for its two hypoglycemia drug candidates, X358 and X129, and a third drug candidate for hypercalcemic endocrine and oncology conditions, will be presented at the Endocrine Society’s 99th Annual Meeting (ENDO 2017), taking place from April 1-4, 2017 in Orlando, Florida.

“We look forward to sharing additional efficacy and safety data on X358 and X129 with the clinical endocrinology community at this year’s ENDO meeting. We are also looking forward to discussing the positive progress and development candidate selection for our anti-PTH1R program targeting serious hypercalcemia associated with hyperparathyroidism and certain malignancies,” said Jim Neal, Chief Executive Officer of XOMA. “This continued positive data positions each of these programs well for partnering activities. Once they are successfully partnered, these programs would expand our portfolio of fully funded programs producing future milestones and royalties that contribute to our goal of delivering positive cash flow and profitability.”

The Company will deliver one oral presentation and three poster presentations, they include:

Oral Presentation Abstract title: Single Administration of XOMA 358, an Insulin Receptor Attenuator, Improves Post-Meal and Nighttime Hypoglycemia Profiles in Post Gastric Bypass Hypoglycemia (PGBH) Patients

  • Session: OR14: Glucose Metabolism and Post Bariatric Surgery
  • Date: Monday, April 3, 2017, 12:30 PM – 12:45 PM
  • Location: OCCC – W224C

Poster Presentations Abstract title: Activity of XOMA 358, an Inhibitor of Insulin Action Following Short-Term Administration to Congenital Hyperinsulinism Patients

  • Session: MON 001-056 Pediatric Endocrine Case Reports: Diabetes, Thyroid, and Beyond
  • Poster number: MON 056
  • Date: Monday, April 3, 2017, 1:00 PM – 3:00 PM
  • Location: West Hall B (EXPO Hall)

Abstract title: XOMA 129, a Novel Insulin Receptor Negative Modulator, Is Efficacious in Treating Insulin- Induced Hypoglycemia in Minipigs

  • Session: SAT 575-585 Cellular Signaling Pathways and Regulation of Glucose Metabolism
  • Poster number: SAT 583
  • Date: Saturday, April 1, 2017, 1:00 PM – 3:00 PM
  • Location: West Hall B (EXPO Hall)

Abstract title: A Novel Anti-PTH1R Receptor Antagonist Monoclonal Antibody Reverses Hypercalcemia Induced By PTH or PTHrP: A Potential Treatment of Primary Hyperparathyroidism and Humoral Hypercalcemia of Malignancy

  • Session: SAT 338-359 Innovations in Bone Biology
  • Poster number: SAT 339
  • Date: Saturday, April 1, 2017, 1:00 PM – 3:00 PM
  • Location: West Hall B (EXPO Hall)

More information about the ENDO program can be found at: http://www.endocrine.org/endo-2017/meeting-program

http://bit.ly/2nbgMxi

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: